Quarterly ResultAug 7, 2026, 08:04 AM
Gyre Therapeutics Q2 Revenue $29.1M, Net Loss $14.3M; Cullgen Acquired
AI Summary
Gyre Therapeutics reported Q2 2026 revenue of $29.1 million, a 2% decrease year-over-year, and a net loss of $14.3 million, significantly wider than the $2.2 million loss in Q2 2025. The company also announced the completion of its acquisition of Cullgen Inc. for approximately $300 million, expanding its pipeline into targeted protein degraders and oncology. Additionally, the New Drug Application for F351 for CHB-induced liver fibrosis was accepted by China’s CDE, and full-year 2026 revenue guidance was affirmed at $100.5 million to $111.0 million.
Key Highlights
- Acquired Cullgen Inc. for approximately $300 million in an all-stock transaction on May 4, 2026.
- Q2 2026 revenue was $29.1 million, a 2% decrease from $29.7 million in Q2 2025.
- Reported a GAAP basic EPS of $(0.12) for Q2 2026, compared to $(0.02) in Q2 2025.
- Net loss for Q2 2026 increased to $14.3 million from $2.2 million in Q2 2025.
- NDA for F351 for CHB-induced liver fibrosis accepted by China’s CDE in May 2026.
- Affirmed full year 2026 revenue guidance of $100.5 million to $111.0 million.
- Cash and equivalents totaled $103.2 million as of June 30, 2026.
- ETUARYTM sales increased to $28.0 million in Q2 2026 from $23.5 million in Q2 2025.
Price Impact
More from GYRE